Gambro signs $142 million loan:
This article was originally published in Clinica
Swedish dialysis company Gambro has signed a 10-year E150m ($142m) loan with the European Investment Bank. The funds will support the company's R&D investments at two new production sites in Lund, Sweden and Hechingen, Germany. The loan will also be put towards the construction of two plants - in Hechingen and Meyzieu, France - for the manufacture of synthetic dialysers.
You may also be interested in...
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.